Herein, we describe a case of tislelizumab-induced SJS/TEN successfully managed with a tumor necrosis factor-α (TNF-α) inhibitor plus hemoperfusion, which, to our knowledge, is the first report detailing the successful use of a TNF-α inhibitor for this specific condition. Here, TNF is linked to toxic epidermal necrolysis.